Results 111 to 120 of about 643 (132)

CORRELACIÓN ENTRE DISLIPIDEMIAS Y TIEMPO DE USO DE BIKTARVY EN PACIENTES CON VIH DEL HGR 1 CHIHUAHUA.

Revista sanitaria de investigación
Introducción: La terapia antirretroviral ha mejorado la supervivencia en pacientes con VIH; sin embargo, algunos esquemas como Biktarvy pueden asociarse a alteraciones metabólicas, particularmente dislipidemias, incrementando el riesgo cardiovascular. Objetivo: Analizar la correlación entre dislipidemias y el tiempo de uso de Biktarvy en pacientes con ...
Jorge López Leal, Ana Marlend Rivas Gómez, José Luis Gutiérrez Rubio   +2 more
openaire   +1 more source

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Blood
Background: North American Adult T-cell leukemia/lymphoma (NA-ATLL) is a rare and aggressive malignancy of CD4+ T-cells associated with HTLV-I infection. Despite varied treatment approaches, acute ATLL has an overall survival of less than one year.
Nechama Dreyfus, Emma Cordover, Kith Pradhan, Latoya S Townsend, Mendel Goldfinger, Ioannis Mantzaris, Nishi Shah, Aditi Shastri, Noah Kornblum, Dennis L Cooper, Ridhi Gupta, Lauren Shapiro, Kira Gritsman, Marina Konopleva, Beth McLellan, Simon Zhen, Alyssa de Castro, Salvatore Lia, Virleny Garcia, Roy Browne, Eric Meyerowitz, Yoram Puius, Margaret McCort, Yang Shi, Yanhua Wang, Amit Verma, B. Hilda Ye, Murali Janakiram, Abdul-Hamid Bazarbachi, R. Alejandro Sica   +29 more
openaire   +1 more source

4. Viral Suppression in Youth Living with HIV: Predictors and Outcomes from the Biktarvy Outcomes in Baltimore Youth Study (B.O.B.Y.)

Journal of Adolescent Health
exaly   +2 more sources

Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV‐1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study

HIV Medicine
AbstractBackgroundStudies on switching to tenofovir alafenamide (TAF)‐based regimens raise concerns about a worse metabolic profile in people with HIV, even though most received tenofovir disoproxil fumarate (TDF) in their previous regimen. This study aims to evaluate changes in lipid fractions, glucose, and serum markers for hepatic steatosis (HS ...
C. Busca‐Arenzana, D. Ortega‐González, M. Díaz‐Almirón, M. L. Montes, Luz Martin‐Carbonero, R. Mican, R. Montejano, L. Ramos‐Ruperto, Eulalia Valencia, Ana Delgado‐Hierro, Jose I. Bernardino   +10 more
openaire   +2 more sources

560: SEVERE LACTIC ACIDOSIS DUE TO INAPPROPRIATE BIKTARVY USE IN A PATIENT WITH HIV

Critical Care Medicine, 2023
Andrew Strike, Nicole McGuire, Gabriel Velez Oquendo, Sarika Chowdry, Yalew Debella   +4 more
openaire   +1 more source

P015 The safety and efficacy of the use of Biktarvy with boosted darunavir in clinical practice

2022
Tyler, Stephanie, Collins, Nadine, Barchi, William, Ranjababu Kulasegaram   +3 more
openaire   +1 more source

Bioequivalence of Solid/Crushed/Dissolved Forms of Biktarvy®

Case Medical Research, 2020
openaire   +1 more source

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

Case Medical Research, 2020
openaire   +1 more source

Acute Liver Failure from Reactivation of Hepatitis B Virus Infection Secondary to Non adherence with Biktarvy

2022
Anisha Garg, Rishabh Bansal, Shreyas Kalantari, Ravitej Khunkhun   +3 more
openaire   +1 more source

Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy

Case Medical Research, 2019
openaire   +1 more source